[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Other Articles
March 18, 1939


Author Affiliations


From the Third Surgical Division, Bellevue Hospital.

JAMA. 1939;112(11):1044-1045. doi:10.1001/jama.1939.02800110024005

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


Bellevue Hospital annually treats about 600 patients with erysipelas. Prior to 1937 the treatment of this disease was varied and not particularly effective. Erysipelas antitoxin, ultraviolet rays and local treatment of various kinds had all proved to be more or less ineffectual.

With the advent of sulfanilamide (prontylin and its related compound prontosil [the disodium salt of 4-sulfamidophenyl-2'-azo-7'-acetylamino-l'-hydroxynaphthalene-3,'6'disulfonic acid] ) new hope was held for controlling this disease. Enough has been said and written about these drugs to preclude any detailed discussion of their action here. Their effect on hemolytic streptococci and other bacteria is by now well known.

Beginning Jan. 1, 1937, all patients with erysipelas entering Bellevue Hospital were treated with sulfanilamide (prontylin and its derivative prontosil; prontylin in tablet form for oral use and prontosil for intramuscular injection). At first dosage was a problem, but in a short time a definite plan of treatment was formulated and has

First Page Preview View Large
First page PDF preview
First page PDF preview